Shilpa Medicare Limited
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.
What Shilpa files
- Important41
- Updates40
- Others36
- Investor Meet26
- Board Meeting14
- PPTs8
Shilpa Medicare announced its 39th Annual General Meeting (AGM) on September 11, 2026. The Annual Report for FY25-26 is available, providing investors key insights into the company's financial performance.
Shilpa Medicare voluntarily recalled ~27,900 vials of a chemotherapy drug in the US due to discoloration. This Class II recall is not expected to materially impact the company's financial position or operations.
Shilpa Medicare's board proposed a dividend of Re. 0.60 per share for FY26. Shareholders are informed about Tax Deducted at Source (TDS) on this dividend. Update PAN and submit tax exemption documents promptly to ensure correct TDS rates.
Shilpa Biologicals partnered with Orion to co-develop and supply a Nivolumab biosimilar for Europe. Shilpa will lead development & manufacturing, earning milestone payments and supply revenue from this significant ~$4.1 billion market.
Shilpa Medicare's subsidiary commissioned a state-of-the-art ADC GMP Manufacturing Facility. This positions the company as a leading integrated CDMO for high-value oncology biologics, expanding capabilities for global pharma partners.